Back to Search
Start Over
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma
- Source :
- Biology of Blood and Marrow Transplantation. 21(9):1583-1588
- Publication Year :
- 2015
- Publisher :
- Elsevier BV, 2015.
-
Abstract
- Many patients with lymphoma relapse after autologous stem cell transplantation (AutoSCT). These patients are often considered for allogeneic stem cell transplantation (AlloSCT) if remission can be achieved. If a tandem approach was organized, some cases of relapse might be prevented. We conducted a phase II trial of tandem AutoSCT followed by reduced-intensity conditioning (RIC) AlloSCT for patients with high-risk lymphoma. High-dose chemotherapy was given with busulfan, cyclophosphamide, and etoposide. AlloSCT was composed of RIC with busulfan/fludarabine and tacrolimus, sirolimus, and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Donors were fully matched related or unrelated donors. AlloSCT was performed any time between 40 days and 6 months after AutoSCT. Forty-two patients were enrolled, and all patients underwent AutoSCT. RIC AlloSCT was performed in 29 patients. In the 29 patients who underwent tandem transplant, median time from AutoSCT to AlloSCT was 96 days (range, 48 to 169). The 6-month cumulative incidence of grades II to IV acute GVHD was 13.8% (90% confidence interval [CI], 5.3% to 26.3%). Cumulative incidence of chronic GVHD at 1 year was 37.9% (90% CI, 23.1% to 52.7%). Nonrelapse mortality at 2 years after AlloSCT was 11.1% (90% CI, 3.5% to 23.6%). At a median follow-up of 30 months (range, 17.1 to 51.5) for the entire group, the 2-year progression-free survival rate was 64% (90% CI, 50% to 75%) and the 2-year overall survival rate was 69% (90% CI, 43% to 85%). For the 29 patients who underwent tandem SCT, the 2-year progression-free survival rate was 72% (90% CI, 55% to 83%) and the 2-year OS rate was 89% (90% CI, 74% to 96%). Tandem AutoSCT–RIC AlloSCT appears to be safe and effective in patients with high-risk lymphoma. Prospective trials using such an approach in specific lymphoma subtypes are warranted.
- Subjects :
- Adult
Male
medicine.medical_specialty
Lymphoma
medicine.medical_treatment
Graft vs Host Disease
Gastroenterology
Disease-Free Survival
Tacrolimus
Tandem transplant
Autologous stem-cell transplantation
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Cumulative incidence
Autografts
Busulfan
Survival rate
Etoposide
Aged
Sirolimus
Chemotherapy
Transplantation
Auto-allo
business.industry
Hematology
Middle Aged
Allografts
Surgery
Fludarabine
Survival Rate
Reduced-intensity conditioning
Methotrexate
Female
business
Vidarabine
Follow-Up Studies
Stem Cell Transplantation
medicine.drug
Subjects
Details
- ISSN :
- 10838791
- Volume :
- 21
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Biology of Blood and Marrow Transplantation
- Accession number :
- edsair.doi.dedup.....585c22314337fc21b33b2cdb4fcd62a2
- Full Text :
- https://doi.org/10.1016/j.bbmt.2015.05.016